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2A general model for the ontogenetic growth of living organisms has been recently
proposed. Here we investigate the extension of this model to the growth of solid malignant
tumors. A variety of in vitro and in vivo data are analyzed and compared with the prediction
of a 'universal' law, relating properly rescaled tumor masses and tumor growth times. The
results support the notion that tumor growth follows such a universal law. Several important
implications of this finding are discussed, including its relevance for tumor metastasis and
recurrence, cell turnover rates, angiogenesis and invasion.
A better understanding of the growth kinetics of malignant tumors is of paramount
importance for the development of more successful treatment strategies. Given the lack of clinical
data at non-symptomatic stages, it has been conjectured, that in most solid malignant human tumors
two or three decades elapse between the first carcinogenic stimulus and the clinical emergence of
the neoplasm (Tubiana, 1986). Since a tumor is clinically detectable with conventional diagnostic
tools at approximately 1 cm3 in volume, representing a population of about 1 billion cells, some 30
cell doublings from the progenitory cancer cell must occur in order to reach this ‘diagnostic’ stage.
Assuming typical volume doubling times of about 100 days, this scenario corresponds to a
preclinical time of roughly 8 years . In the next 10 volume doublings up to about 103 cm3 in size
(which is reportedly lethal in primary breast cancer by Retsky, 1997), the clinical history of the
tumor passes through a microscopic, avascular growth phase, followed by angiogenesis, necessary
to sustain a macroscopic size (Folkman, 1971).Continuous tumor progression leads then eventually
to local tissue invasion and metastasis, depending on the particular cancer type.
A recent paper from West et al (2001) shows that, regardless of the different masses and
development times, mammals, birds, fish and molluscs all share a common growth pattern.
Provided that masses and growth times for the different organisms are properly rescaled, the same
universal exponential curve fits their ontogenetic growth data. The authors explain this phenomenon
with basic cellular mechanisms (West et al, 2002), assuming a common fractal pattern in the
vascularization of the investigated taxa.
Since rapid volumetric growth and neovascularization are also hallmarks of solid malignant
tumors, it is intriguing to investigate whether tumor growth follows the same universal curve. For
this purpose we rescale tumor sizes and growth times according to West's recipe (West et al, 2001),
which we briefly recall here. Instead of the actual mass, m, they use the ratio  r = (m/M)0.25 , where
M is the asymptotic mass for the taxon; r relates to the relative proportion of total energy
expenditure, which is required to ensure maintenance. Likewise, instead of the actual time, t, these
authors use the rescaled dimensionless time
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where r0 = (m0/M)0.25, m0 is the mass at birth, a = 0.25 a m0 –0.25 and a is a parameter, which is
roughly constant within a taxon and proportional to the organism’s metabolic rate across taxa. The
values of a, m0 and  M are reported for many different species in West et al (2001). Using the
variables t and r , this 'universal' growth law follows:
r = 1 – exp (-t) [2]
In our case, m0 and M are the initial and final masses of the tumor, and a is a parameter expected to
be related to the tumor’s characteristics (e.g., its ability to metastasize or invade, or its affinity for
nutrients uptake). Since the definition of the parameters is non-trivial, a multistep fitting procedure
is adopted for their determination. From equations [1] and [2] we obtain:
y = - a r0 t + y0    [3]
where y = ln (1 – r) , y0 = ln (1 – r0). Available data normally provide m as a function of t during
the tumor’s growth phase. For our fitting procedure, the lowest and largest values of m are first
assumed for m0 and M, respectively, thus yielding a preliminary estimate for  y0  and a. Then m0 and
M are allowed to respectively decrease and increase, and y0 and a reestimated until a best-fit
(consistent with the available biological infomation) is obtained.
For our analysis, we have used available data from the literature, spanning in vitro
experiments (multicellular tumor spheroids (Chignola et al, 2000, Nirmala et al, 2001) as well as in
vivo data (both, from animal models (Steel, 1977; Cividalli et al, 2002) and patients(Norton, 1988;
Yorke et al, 1993). The results are presented in Figures 1, 2 and 3, respectively, and plotted against
equation [2]. The data fit the universal growth curve very well. Table 1 presents an estimate of the
relevant parameters and, further supporting our claim, shows very high R2 correlation coefficients
between actual and fitted data.
In the following, we will briefly discuss possible implications of our conjecture that tumor
growth also follows a universal law.
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4a) tumor metastasis and recurrence. Some forty years ago Romsdahl et al. (1961) had
proposed that, upon reaching a certain “critical” volume of the primary tumor, metastatic
dissemination would start. Tubiana (1986) evaluated this threshold for breast cancer, and showed
that it critically depends on the axillary lymph-node involvement. The hypothesis that metastatic
behaviour could be associated with a universal growing phase of the tumor is corroborated by
experimental evidence. For example, data from C3Hf/Sed mice inoculated with fibrosarcoma
(FSall) and squamous cell carcinoma (SCCVII) (Ramsay et al, 1988) show that, if primary tumors
are treated upon reaching a diameter of 6 mm, the maximal percentage of metastasis is only 3.1% in
FSall and 8.0% in SCCVII, while it increases to 14.3% and 41.3%, respectively, if the treatment
starts at a diameter of 12 mm. When local recurrence of the same tumor lines are considered, the
percentage of metastasis, at a tumor diameter of 6 mm, is only 12.5% in FSall and 43.0% in
SCCVII, respectively, versus 46.6% and 70.3% at a diameter of 12 mm. Furthermore, the diameter
doubling time (± standard deviation) necessary to grow from 6 to 12 mm increases from D tp=6.6 (±
0.4) days in primary to D tr=13.6 (± 4.6) days in recurrent Fsall tumors, and from D tp=7.7 (± 0.5)
days to D tr=12.8 (± 3.8) days in SCCVII, respectively. An approximate computation from our
model yields D tr / D tp ~ 1.7, which is in agreement with experimental results from Ramsay et al
(1988). Hence, the recurrent cancer grows much slower than the primary tumor. Following the
notion of a universal law, a possible explanation for this behavior is that the residual clonogenic
cells of the primary tumor, which lead to recurrence, generate cells belonging to an ‘older’
developmental phase.
b) cell turnover rates. As another consequence of the model, the relative amount of energy
devoted to tumor growth, R = 1 – r  can be related to the proportion DN/N of the cells contributing
to the growth at any 'rescaled time', t :
N
N
R
D
»-= )exp( t  [4]
Here, N is the total number of tumor cells and DN is the difference between the rates of newly
generated tumor cells (growth fraction (GF)) and tumor cells being lost (i.e., cell loss factor (CLF),
which includes both cell death and cell invasion). Eq. [4] predicts that DN is larger at the onset of
tumor growth, and decreases exponentially afterwards. In fact, data from glioblastoma spheroids
(Nirmala et al, 2001) suggest values for DN/N ranging from 0.9 at 1 week to 0.35 after 4 weeks.
Moreover, knowing the rate of cell turnover at any developmental stage can help to improve
5therapeutic strategies. As such, we may define the 'lethal' dose of a given therapeutic agent as the
dose D for which the rate of tumor growth post treatment, GF(D) equals the rate of CLF. GF(D)
depends then on both the developmental stage of the tumor (i.e., t) and on its therapeutical
response. If we further assume a given survival fraction SF(D) (different for each tumor), when a
dose D has been administered, then GF(D) should become equal to the GF of the untreated tumor
multiplied by SF(D). There is, however, a threshold time (corresponding to the “critical” tumor
volume at inception of metastasis), before which the dose D is curative, while later it can only be
locally effective. A longitudinal study of the metastasis-free survival in prostate carcinoma (Fuks et
al, 1991) in 679 patients has shown that after 5, 10 and 15 years the percent survival of local control
(LC) cases was 90%, 82% and 77%, respectively, while for local failure (LF) cases it was 68%,
39% and 24%, respectively. One could therefore argue that the LC tumors were correctly treated
(i.e., at doses larger than the lethal one) early on and that only in a small percentage of patients was
the metastasis threshold already surpassed at the time of treatment. Conversely, LF doses were
inadequate and therefore, as the tumor mass continues to grow, metastases were inevitable.
c) angiogenesis.  It is noteworthy that West 's model applies to organisms growing in
unrestricted dietary conditions. Correspondingly, only fully replenished tumors should follow the
universal growth curve. And in fact, as Freyer and Sutherland (1986) pointed out, differences in
growth rates and saturation sizes (of up to a factor of 500) were found comparing tumor spheroids
cultured in media with different oxygen and glucose concentrations. As such, deviations from the
universal curve are conceivable depending on the particular environmental conditions. Our
formalism may yield a simple mathematical explanation for such growth behavior. From the
definition of r follows:
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likewise, from the expression of M as a function of the metabolic rate in West et al  (2001) of a
single cell Bc we deduce that also
0/ <cdBdM    [6]
Thus, if the average value of Bc decreases, such as due to the depletion of a e.g. non-replenished
nutrient concentration, the r curve is bound to shift downwards. Therefore, as “ontogenetic” tumor
growth should depend on the availability of nutrient replenishment or, in vivo, on the successful
6competitition for available nutrients, any marked deviation between the universal and the real
growth curve may indicate the amount of additional nutrients necessary to satisfy the metabolic
demand of the growing tumor. Accordingly, one can further hypothesize that in vivo the degree of
deviation from the universal curve may in fact relate to the amount of paracrine endothelial cell
growth factors (e.g., VEGF (Plate et al, 1992; Shweiki et al, 1992) released by the nutrient-deprived
tumor cells in order to induce the extent of neovascularization necessary to provide the required
level of nutrient replenishment. It is noteworthy that the importance of nutrient availability has been
pointed out also by a model proposed by Delsanto et al. (2000) and Scalerandi et al (1999, 2001)
where, following the Local Interaction Simulation Approach (LISA) (Schechter et al, 1994), a
consistent set of rules governing the microscopic interactions (at the cellular level) has been
formulated, amenable to direct numerical simulations of cancer growth both in the avascular and
vascular case.
d) Invasion. Finally, our findings also relate to cell motility, another hallmark of malignant
tumors. Extracellular matrix-degrading invasive cells are likely to decrease the mechanical
confinement around the tumor. These cells also appear to follow specific routes of dissemination,
which include the perivascular space in the case of malignant astrocytomas (Bernstein et al, 1989;
Vajkoczy et al, 1999). As such, at least in this case, tissue invasion should facilitate further growth
by reducing the constraint of confinement not only for the volumetrically expanding tumor itself but
also for the aforementioned chemo-attracted endothelial cells, which migrate towards the
angiogenic factor releasing tumor cells. Thus, a progressive decrease in Bc may not only trigger an
increase in (e.g.) VEGF secretion, but could also induce an increase in the extent and dynamics of
tissue invasion, which in turn facilitates angiogenesis and ensures continuing tumor growth.
Therefore, not only metastasis and angiogenesis but also tumor cell invasion may be linked to a
“critical” tumor volume, as has already previously been argued on the basis of experimental
findings from human glioma spheroids (Deisboeck et al, 2001).
In summary, we have investigated the applicability of West’s general model for the
ontogenetic growth of living organisms to the case of solid malignant tumors. The results from
fitting a variety of in vitro data from multicellular tumor spheroids and of in vivo data from both
experimental models as well as patients support the notion that neoplasms also follow a universal
growth law. Our paradigm-shifting finding has far-reaching implications concerning the mechanism
of tumor metastasis and recurrence, cell turnover, angiogenesis and invasion.
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FIGURE CAPTIONS:
Fig. 1. Tumor growth curves (replenished multicellular tumor spheroids). r = (m/M) 0.25 vs the
'rescaled' time t for various multicellular spheroids. Rat gliosarcoma (9L) and human glioblastoma
(U118)  were cultured over 60 days on agarose with the medium superlayer routinely replaced every
seven days (Chignola et al, 2000). The fitting lines were obtained by the same authors using a
Gompertzian model. Data from another human glioblastoma line (SNB19) (Nirmala et al, 2001),
cultured over a shorter time (30 days, with the cell culture medium  replenished once every other
day) and reaching a maximum volume of about 0.15 mm3 are also included. In spite of the different
dimensions (after 30 days, the 9L and U118 spheroids measured 0.5 mm3 and 0.9 mm3,
respectively), all data fit well eq.[2], which is also plotted for reference.
Fig. 2. Tumor growth curves (rodent models). Fibroadenoma (Fibro) and Walker carcinoma
(Walker) were transplanted into rats: their initial tumor volumes ranged from 0.1 (Walker) to 1 cm3
(Fibro), and final volumes approached 100 cm3  after 180 days and 25 days, respectively (Steel,
1977). The other murine tumors: a mammary adenocarcinoma (KHJJ), a mammary carcinoma
(C3H), a sarcoma (EMT6) and two osteosarcomas (NCTC2472 and osteo) had initial volumes
ranging between 0.001 and 0.05 cm3 and final volumes of 1 to 5 cm3, after an elapsed time between
10
15 and 100 days, depending on the tumor (Steel, 1977). Additional data on another murine
mammary carcinoma (Ch3 ISS) (Cividalli et al, 2002) are also included. Eq [2] is again plotted for
reference.
Fig. 3. Tumor growth curves (breast and prostate tumors from patients). Data are extrapolated using
the Gompertzian curve parameters (Norton, 1988; Yorke et al, 1993). For patient data the analysis is
more difficult, since often only few observations of the same untreated tumor are available and the
tumor’s asymptomatic hystory is unknown. As in the previous figures, Eq [2] is plotted here for
reference.
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TABLE 1: Estimates of the relevant parameters from Figures 1-3. An asterix * in the
second column denotes in vivo data. The values of the parameters m0, M and a are estimated by
means of the fitting procedure described after eq. [3]. R2 represents the correlation coefficient
between actual and fitted data.
Tumor Reference mo(g) M(g) a (g 0.25 /day) R2
9L  (exp) Chignola, 2000 0.000037 0.000515 0.102 0.69
9L (fitted) Chignola, 2000 0.0000189 0.000515 0.114 0.99
U118 (exp) Chignola, 2000 0.000037 0.000812 0.084 0.64
U118 (fitted) Chignola, 2000 0.0000605 0.000823 0.084 0.98
SNB19 Nirmala,2001 0.025 3 0.075 0.96
fibro Steel,1977 * 1 200 0.14 0.95
walker Steel,1977 * 0.348 150 1.54 0.97
KHJJ Steel,1977 * 0.0012 2 0.23 0.99
C3H Steel,1977 * 0.0348 5 0.21 0.98
EMT6 Steel,1977 * 0.00135 3 0.5 0.99
NCTC 2472 Steel,1977 * 0.052 7 0.49 0.99
osteo Steel,1977 * 0.0058 7 0.124 0.92
C3H ISS Cividalli, 2002* 0.2 8 0.37 0.95
human breast Norton, 1988 * 1 646 0.81 0.97
human prostate Yorke, 1993 * 1 641 0.42 0.85
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